Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of Ii-Key-SARS-CoV-2 vaccine

Next Previous
X
Search
Trial Profile

A clinical study of Ii-Key-SARS-CoV-2 vaccine

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ii-Key-SARS-CoV-2 peptide vaccine (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions

    • Most Recent Events

    • 20 Jul 2020 According to a Generex Biotechnology Corporation media release, the company has submitted a pre-IND briefing package to FDA requesting regulatory guidance on this trial protocol and clinical development plan for the Ii-Key-SARS-CoV-2 coronavirus prophylactic vaccine.
    • 17 Apr 2020 New trial record
    • 14 Apr 2020 According to a Generex Biotechnology Corporation media release, the company is in discussions with the U.S. government about funding vaccine development program and speaking with people at Health Canada this week to discuss the Canadian regulatory path for approval in Canada.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top